Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes

Intravitreal Ranibizumab (Lucentis) monotherapy is currently the standard of care for neovascular age-related macular degeneration (AMD), supported by well-conducted clinical trials and non-randomised studies. 1-4 Visual and anatomical outcomes are definitely better than Verteporfin Photodynamic the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of ophthalmology 2010-11, Vol.94 (11), p.1543-1545
Hauptverfasser: Raja, M S A, Saldana, M, Goldsmith, C, Burton, B J L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!